Tariffs and Trade Series: What Investors Need to Know
Tariffs and Trade Series: What Senior Management Teams Need to Know
Daily Compliance News: May 7, 2025 the Private Lives Edition
Wiley's 2025 Key Trade Developments Series: Trade Remedies
Wiley's 2025 Key Trade Developments Series: U.S.-Mexico-Canada Agreement (USMCA)
Wiley's 2025 Key Trade Developments Series: Tariffs
Daily Compliance News: April 24, 2025, The Made in Malaysia Edition
Daily Compliance News: April 22, 2025, The Upping Your Game Edition
Compliance Tip of the Day: The Role of Supply Chain and Compliance in Tariffs
Compliance Tip of the Day: Essential Economic Data for Navigating Tariffs
Compliance Tip of the Day: Role of Compliance in Upcoming Trade Wars
Tariffs and Trade Series: Effects on Agriculture Operations and Markets
Tit For Tat US China Trade War
Compliance Tip of the Day: Navigating Uncertainty During Trump’s Tariffs
Daily Compliance News: April 14, 2025, The Cascade of Corruption Edition
Episode 364 -- Five Strategies to Mitigate a New Risk Environment
Sunday Book Review: April 13, 2025, The Books on Trade and Tariffs Edition
10 For 10: Top Compliance Stories For the Week Ending April 12, 2025
Daily Compliance News: April 11, 2025 The Tariff Rollback Edition
Are We Having Fun Yet?
Key Takeaways - Regulatory Relief for U.S. Manufacturing: The EO streamlines FDA and EPA processes to encourage domestic pharmaceutical production....more
Over the first 100 days and beyond, the Trump Administration has deployed national security authorities in novel ways. Perhaps most notably, President Trump has asserted authority under the International Emergency Economic...more
Recently, underscoring a commitment to national security, the White House and the Food and Drug Administration (FDA) issued separate communications that aim to bolster domestic drug manufacturing while tightening oversight of...more
On May 5, 2025, President Donald J. Trump issued Executive Order (“EO”) 14293 entitled Regulatory Relief to Promote Domestic Production of Critical Medicines. The EO directs the U.S. Food and Drug Administration (“FDA”), U.S....more
The White House on May 5, 2025 issued an executive order requiring the US Food and Drug Administration to find ways to facilitate the opening of new drug manufacturing sites in the United States while also increasing the...more
The first 100 days of the second Trump Administration have been marked by a flurry of Executive Orders (EOs) and policy memoranda intended to advance President Donald Trump’s “America First” agenda. In the process, these...more
On April 9, 2025, President Trump signed an Executive Order (the “EO”) entitled Restoring America’s Maritime Dominance. The EO directs the creation of a comprehensive Maritime Action Plan aimed at revitalizing U.S. maritime...more
Littler's Executive Order Tracker is your go-to resource for staying up to date on all executive orders and actions issued by the Trump administration. We are tracking every order, analyzing its impact, and providing...more
The Trump administration has intensified its America First Trade Policy initiatives by announcing three new investigations under Section 232 of the Trade Expansion Act of 1962 by the Department of Commerce. As foreshadowed in...more
Not long after announcing new global “reciprocal” tariffs on imports from around the world at the beginning of April 2025, which we previously reported in a recent eUpdate, President Trump began modifying that tariff action....more
On April 23, the U.S. Department of Commerce (Commerce) announced its initiation of investigations into the national security effects of imports of critical minerals and medium/heavy trucks, parts for such goods, and their...more
Section 232 investigations determine whether the targeted U.S. imports threaten to impair U.S. national security. At the conclusion of a Section 232 investigation (which can last for up to 270 days), the President must...more
The Trump administration is pursuing additional national security investigations that will likely lead to tariffs on imports of semiconductors, semiconductor manufacturing equipment (“SME”), and derivative articles,...more
Over the past few weeks, the Trump Administration has announced three new investigations under Section 232 of the Trade Expansion Act of 1962 into whether imports of pharmaceuticals, semiconductors, and critical minerals and...more
Following up on our previous article, "To Tariff, or Not to Tariff", the President issued a new Executive Order on April 15 requesting the Secretary of Commerce commence an investigation into the national security risks from...more
Last week, President Trump issued several executive orders in furtherance of his policy aims, including orders relating to increasing efficiency in the government contracting process, assessing the impact of importation of...more
Effective April 5, the United States imposed a 10% baseline tariff on imports from nearly all countries, excluding products from Canada and Mexico, and those products contained in the Harmonized Tariff Schedule of the United...more
The Department of Commerce (Commerce) has launched three Section 232 investigations covering pharmaceuticals, pharmaceutical ingredients, and their derivative products; semiconductors and semiconductor manufacturing equipment...more
The Department of Commerce’s Bureau of Industry and Security (“BIS”) has initiated a Section 232 investigation of imports of semiconductors and semiconductor manufacturing equipment. According to the Federal Register notice...more
This article provides an overview of the most recent tariff updates affecting businesses operating within the semiconductor, pharmaceutical, and critical mineral industries. Below we outline recent tariff exclusions for...more
The Trump Administration has formally launched three separate national security investigations under Section 232 of the Trade Expansion Act of 1962 including on: 1) imports of semiconductors (including downstream electronic...more
On April 15, 2025, President Trump directed the Secretary of Commerce to initiate an investigation under Section 232 of the Trade Expansion Act of 1962 examining the threats to national security from imports of processed...more
The U.S. Department of Commerce announced that it has initiated a Trade Expansion Act of 1962 Section 232 investigation to determine whether imports of pharmaceutical products and ingredients pose a national security risk to...more
On April 14, 2025, the US Department of Commerce Bureau of Industry and Security (BIS) announced the initiation of investigations into the effects on US national security of imports of pharmaceuticals and pharmaceutical...more
On April 15, 2025, the Trump Administration issued an Executive Order (EO) directing the Secretary of Commerce to initiate an investigation under Section 232 of the Trade Expansion Act of 1962 (Section 232), to determine...more